Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3199863 | 0.77 | POLB (0.57) | POLBSMN1; SMN2CXCR4SIGMAR1CHRM5 | |
| SCHEMBL965730 | 0.77 | — | — | |
| SCHEMBL1135559 | 0.76 | LMNA (0.40) | LMNAPOLBSMN1; SMN2CXCR4SIGMAR1 | |
| SCHEMBL968051 | 0.75 | LMNA (0.65) | LMNACHRM5CHRM3CHRM2CHRM1 | |
| SCHEMBL17269556 | 0.74 | LMNA (0.44) | LMNAPOLBSMN1; SMN2CXCR4SIGMAR1 | |
| SCHEMBL9281479 | 0.74 | LMNA (0.44) | LMNAPOLBSMN1; SMN2CXCR4SIGMAR1 | |
| Hydrochloric Acid SCHEMBL8665853 | 0.74 | SMN1; SMN2 (0.39) | LMNAPOLBSMN1; SMN2CXCR4SIGMAR1 | |
| Hydrochloric Acid SCHEMBL2973746 | 0.73 | LMNA (0.42) | LMNAPOLBSMN1; SMN2CXCR4SIGMAR1 | |
| SCHEMBL1776726 | 0.72 | — | — | |
| SCHEMBL2230934 | 0.71 | ALDH1A1 (0.47) | LMNAPOLBSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3153023-B1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | TAKEDA PHARMACEUTICALS CO (JP) | 2022-03-16 | — | — | EP | disclosed |
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | INTELLIKINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| EP-2252293-B1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2017-07-27 | — | — | US | disclosed |
| US-9682141-B2 | Combination of kinase inhibitors and uses thereof | INTELLIKINE LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9669032-B2 | Enhanced treatment regimens using mTOR inhibitors | INTELLIKINE LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9637492-B2 | Benzothiazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-05-02 | — | — | US | disclosed |
| EP-3153023-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | Intellikine, LLC (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-2705181-B1 | COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | INTELLIKINE LLC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160287596-A1 | Benzoxazole Kinase Inhibitors and Methods of Use | FAETH THERAPEUTICS, INC. | 2016-10-06 | — | — | US | disclosed |
| WO-2012154608-A1 | REACTIVE MTOR AND PI3 KINASE INHIBITORS AND USES THEREOF | INTELLIKINE, LLC (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012154610-A1 | REACTIVE PI3K KINASE INHIBITORS AND USES THEREOF | INTELLIKINE, LLC (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012151562-A1 | COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | INTELLIKINE, LLC (US) | 2012-11-08 | — | — | WO | disclosed |
| EP-2365750-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | Intellikine, Inc. (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-03-31 | — | — | US | disclosed |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-22 | — | — | US | disclosed |
| WO-2010051043-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010051042-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287596-A1 | Benzoxazole Kinase Inhibitors and Methods of Use | BMX, MTOR, PDPK1 | LMNA 3015/4885POLB 3912/4885SMN1; SMN2 4736/4885 |
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | BMX, MTOR, PDPK1 | LMNA 3015/4885POLB 3912/4885SMN1; SMN2 4736/4885 |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K1, PDPK1 | LMNA 2831/4885POLB 1654/4885SMN1; SMN2 4472/4885 |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | MTOR, PDPK1, PIKFYVE | LMNA 3843/4885POLB 3346/4885SMN1; SMN2 4783/4885 |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | BMX, MTOR, PDPK1 | LMNA 3015/4885POLB 3912/4885SMN1; SMN2 4736/4885 |
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | CDC25C, CCNC, CDC25B | LMNA 1699/4885POLB 313/4885SMN1; SMN2 2870/4885 |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | MPL, MTX2, SLC10A1 | LMNA 3292/4885POLB 1201/4885SMN1; SMN2 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.